Every Form 4 that TuHURA Biosciences, Inc. (HURA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HURA filings page.
TuHURA Biosciences Chief Executive Officer James A. Bianco reported a bona fide gift of 150,000 shares of TuHURA Biosciences common stock. The shares were transferred on May 28, 2026 and, according to the disclosure, were gifted to adult sons who do not share the same household.
Following this gift, Bianco directly holds 2,173,307 shares of TuHURA Biosciences common stock. Because this was a gift with no sale proceeds, it reflects a personal transfer of ownership rather than a market transaction in the company’s stock.
Tendler Craig reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Ng George K reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Hoffman Robert E. reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn. On January 6, 2026, he was granted 273,696 options (right to buy common stock) with an exercise price of $0.73 per share, expiring on January 6, 2036. The options were acquired at no cost and are held directly. According to the footnote, this is a supplemental option grant to an option grant previously made in December 2025, and one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Executive Officer and director, James A. Bianco. On January 6, 2026, he received an award of 610,332 stock options (options right to buy common stock) with an exercise price of $0.73 per share and an expiration date of January 6, 2036. The options were granted at no cost as a supplemental option grant to one previously made in December 2025.
According to the disclosure, one-third of these stock options become exercisable on the first, second, and third anniversary of January 6, 2025, creating a three-year vesting schedule. Following this grant, Bianco beneficially owns 610,332 derivative securities directly.
TuHURA Biosciences, Inc. (HURA) reported that its Chief Financial Officer, Dan Dearborn, received stock options to purchase 1,531,367 shares of common stock at an exercise price of $1.02 per share on 12/12/2025.
The options are held directly, expire on 12/12/2035, and cover 1,531,367 underlying shares, which is also the number of derivative securities beneficially owned after the transaction. One-third of the stock options becomes exercisable on each of the first, second, and third anniversaries of 12/12/2025, creating a three-year vesting schedule.
TuHURA Biosciences, Inc. insider James Bianco, the company’s chief executive officer and a director, reported acquiring stock options on 12/12/2025. The options give him the right to buy up to 3,414,891 shares of TuHURA common stock at an exercise price of $1.02 per share and are scheduled to expire on 12/12/2035.
According to the filing, these options were acquired in a single transaction coded "A" and had a reported price of $0 for the derivative security itself. A footnote explains that one-third of the options become exercisable on each of the first, second, and third anniversaries of December 12, 2025. Following this transaction, Bianco beneficially owns 3,414,891 stock options directly.